103 related articles for article (PubMed ID: 24803299)
1. Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.
Jorda R; Navrátilová J; Hušková Z; Schütznerová E; Cankař P; Strnad M; Kryštof V
Chem Biol Drug Des; 2014 Oct; 84(4):402-8. PubMed ID: 24803299
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
Manohar SM; Rathos MJ; Sonawane V; Rao SV; Joshi KS
Leuk Res; 2011 Jun; 35(6):821-30. PubMed ID: 21216463
[TBL] [Abstract][Full Text] [Related]
3. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
[TBL] [Abstract][Full Text] [Related]
4. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
Zhou L; Zhang Y; Sampath D; Leverson J; Dai Y; Kmieciak M; Nguyen M; Orlowski RZ; Grant S
Br J Cancer; 2018 Feb; 118(3):388-397. PubMed ID: 29241222
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of CDA-Ⅱ, a urinary preparation, on human multiple myeloma cell lines via the mitochondrial pathway.
Yang M; Huang J; Ma QL; Xu GX; Jin J
Mol Med Rep; 2014 Mar; 9(3):1025-31. PubMed ID: 24452179
[TBL] [Abstract][Full Text] [Related]
6. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
Gojo I; Zhang B; Fenton RG
Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
[TBL] [Abstract][Full Text] [Related]
7. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1.
Polier G; Ding J; Konkimalla BV; Eick D; Ribeiro N; Köhler R; Giaisi M; Efferth T; Desaubry L; Krammer PH; Li-Weber M
Cell Death Dis; 2011 Jul; 2(7):e182. PubMed ID: 21776020
[TBL] [Abstract][Full Text] [Related]
8. The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo.
Xie G; Tang H; Wu S; Chen J; Liu J; Liao C
Int J Oncol; 2014 Aug; 45(2):804-12. PubMed ID: 24865236
[TBL] [Abstract][Full Text] [Related]
9. Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.
Fan F; Tonon G; Bashari MH; Vallet S; Antonini E; Goldschmidt H; Schulze-Bergkamen H; Opferman JT; Sattler M; Anderson KC; Jäger D; Podar K
Cancer Lett; 2014 Feb; 343(2):286-94. PubMed ID: 24120758
[TBL] [Abstract][Full Text] [Related]
10. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
11. The selective P-TEFb inhibitor CAN508 targets angiogenesis.
Kryštof V; Rárová L; Liebl J; Zahler S; Jorda R; Voller J; Cankař P
Eur J Med Chem; 2011 Sep; 46(9):4289-94. PubMed ID: 21777997
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
Natoni A; Murillo LS; Kliszczak AE; Catherwood MA; Montagnoli A; Samali A; O'Dwyer M; Santocanale C
Mol Cancer Ther; 2011 Sep; 10(9):1624-34. PubMed ID: 21768328
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
[TBL] [Abstract][Full Text] [Related]
14. Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction.
Seo SK; Lee HC; Woo SH; Jin HO; Yoo DH; Lee SJ; An S; Choe TB; Park MJ; Hong SI; Park IC; Rhee CH
Apoptosis; 2007 Jan; 12(1):195-209. PubMed ID: 17136320
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
Venkata JK; An N; Stuart R; Costa LJ; Cai H; Coker W; Song JH; Gibbs K; Matson T; Garrett-Mayer E; Wan Z; Ogretmen B; Smith C; Kang Y
Blood; 2014 Sep; 124(12):1915-25. PubMed ID: 25122609
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
17. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members.
Gauduchon J; Gouilleux F; Maillard S; Marsaud V; Renoir JM; Sola B
Clin Cancer Res; 2005 Mar; 11(6):2345-54. PubMed ID: 15788686
[TBL] [Abstract][Full Text] [Related]
18. Triptolide induces apoptotic cell death of multiple myeloma cells via transcriptional repression of Mcl-1.
Nakazato T; Sagawa M; Kizaki M
Int J Oncol; 2014 Apr; 44(4):1131-8. PubMed ID: 24481531
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells.
Cao S; Yu Y; Chen S; Lei D; Wang S; Pan X; Peng J
Biochem Biophys Res Commun; 2017 Jan; 482(4):536-541. PubMed ID: 27847320
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
